Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers

about

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers

Item

http://www.wikidata.org/entity/Q58805531

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@en

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@nl

type

Item

label

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@en

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@nl

prefLabel

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@en

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@nl

P1476

Discontinuation and comparativ ...... te and fingolimod in 2 centers

@en

P2093

Anasua Bandyopadhyay

http://www.w3.org/2001/XMLSchema#string

Brandi Vollmer

http://www.w3.org/2001/XMLSchema#string

Carrie M Hersh

http://www.w3.org/2001/XMLSchema#string

Enrique Alvarez

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Cohen

http://www.w3.org/2001/XMLSchema#string

John R Corboy

http://www.w3.org/2001/XMLSchema#string

Kavita Nair

http://www.w3.org/2001/XMLSchema#string

Robert A Bermel

http://www.w3.org/2001/XMLSchema#string

Robert J Fox

http://www.w3.org/2001/XMLSchema#string

Sam Cohn

http://www.w3.org/2001/XMLSchema#string

P2860

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

P304

292-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/CPJ.0000000000000487

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Ontaneda

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30140580

http://www.w3.org/2001/XMLSchema#string

P932

6105060

http://www.w3.org/2001/XMLSchema#string